Nabriva Therapeutics plc

• Accepted (ET)
• Oct 1810-Q—
  Quarterly update0001558370-23-016524 · 4.5 MB
  SEC(opens sec.gov)
• Jul 318-K—
  Current report0001104659-23-085605 · 853.3 KB
  SEC(opens sec.gov)
• Jul 248-K—
  Current report0001104659-23-083250 · 199.8 KB
  SEC(opens sec.gov)
• Jul 78-K—
  Current report0001104659-23-079156 · 507.6 KB
  SEC(opens sec.gov)
• Jun 18-K—
  Current report0001104659-23-067071 · 199.4 KB
  SEC(opens sec.gov)
• May 2210-Q—
  Quarterly update0001558370-23-010302 · 5.6 MB
  SEC(opens sec.gov)
• Apr 1710-K—
  Annual report0001558370-23-006062 · 11.9 MB
  SEC(opens sec.gov)
• Feb 38-K—
  Current report0001104659-23-010788 · 236.1 KB
  SEC(opens sec.gov)
• Jan 208-K—
  Current report0001104659-23-005144 · 500.6 KB
  SEC(opens sec.gov)
• Jan 98-K—
  Current report0001104659-23-002268 · 259.6 KB
  SEC(opens sec.gov)

• Bolte AxelDirector
• Bourdow Carrie L.Director
• Broom Colin MDDirector
• BURGESS DANIEL DDirector
• CORRIGAN MARKDirector
• Crotty RobertGen Counsel & Corp Secretary
• Dalton LisaDirector
• Dolan DanielChief Financial Officer
• Gelone Steven P.Director
• Guico-Pabia Christine J.Chief Medical Officer

No tickers on record.

• business

  25-28 NORTH WALL QUAY

  DUBLIN, L2, D01 H104

• mailing

  414 COMMERCE DRIVE STE 120

  FORT WASHINGTON, PA, 19034

• Nabriva Therapeutics AG2017-07-10